Table 1.
Incidence of CC factor alterations in GI cancers from cBioPortal.
| GI cancer studies | All non-redundant cancer studies | TCGA, PanCancer Atlas | |||
|---|---|---|---|---|---|
| No. of patients | No. of studies | Genetic alteration frequency of CC | No. of patients | Genetic + expression alteration frequency of CC | |
| Bowel | 6523 | 17 | 5% | 594 | 39% a |
| Stomach | 739 | 5 | 13% | 440 | 37% |
| Esophagus | 3346 | 13 | 5% | 182 | 32% |
| Pancreas | 1233 | 12 | 5% | 184 | 33% |
| Liver | 1333 | 10 | 3% | 372 | 30% |
| Biliary tract | 1913 | 14 | <1% | 36 | 36% |
Genetic alteration rates are derived from all non-redundant studies on each type of GI cancer. Genetic plus expression level alteration frequency is derived from TCGA, PanCancer Atlas study for each type of GI cancer.
a
Indicates data includes mRNA and protein expression (mass spectrometry data) changes.